Anuradha Gupta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8996153/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Polymeric Hydrogels for Controlled Drug Delivery to Treat Arthritis. Pharmaceutics, 2022, 14, 540.	2.0	19
2	WSN based IoT applications: A Review. , 2022, , .		5
3	Inhalable particles containing isoniazid and rifabutin as adjunct therapy for safe, efficacious and relapse-free cure of experimental animal tuberculosis in one month. Tuberculosis, 2021, 128, 102081.	0.8	8
4	Recent advances in nano-engineered approaches used for enzyme immobilization with enhanced activity. Journal of Molecular Liquids, 2021, 338, 116602.	2.3	27
5	Biomaterials as Antigen Delivery Carrier for Cancer Immunotherapy. Macromolecular Research, 2021, 29, 834-842.	1.0	1
6	Hyperbranched Polymer-Functionalized Magnetic Nanoparticle-Mediated Hyperthermia and Niclosamide Bimodal Therapy of Colorectal Cancer Cells. ACS Biomaterials Science and Engineering, 2020, 6, 1102-1111.	2.6	34
7	Inorganic nanoparticles for natural product delivery: a review. Environmental Chemistry Letters, 2020, 18, 2107-2118.	8.3	32
8	Inorganic Particles for Delivering Natural Products. Sustainable Agriculture Reviews, 2020, , 205-241.	0.6	2
9	Nanocarrier Composed of Magnetite Core Coated with Three Polymeric Shells Mediates LCS-1 Delivery for Synthetic Lethal Therapy of BLM-Defective Colorectal Cancer Cells. Biomacromolecules, 2018, 19, 803-815.	2.6	39
10	Synthetic Lethality: From Research to Precision Cancer Nanomedicine. Current Cancer Drug Targets, 2018, 18, 337-346.	0.8	17
11	Dextrose modified flexible tasar and muga fibroin films for wound healing applications. Materials Science and Engineering C, 2017, 75, 104-114.	3.8	14
12	Pharmacokinetics, Metabolism, and Partial Biodistribution of "Pincer Therapeutic―Nitazoxanide in Mice following Pulmonary Delivery of Inhalable Particles. Molecular Pharmaceutics, 2017, 14, 1204-1211.	2.3	8
13	Preparation and Preclinical Evaluation of Inhalable Particles Containing Rapamycin and Anti-Tuberculosis Agents for Induction of Autophagy. Pharmaceutical Research, 2016, 33, 1899-1912.	1.7	31
14	Inhalable Particles for "Pincer Therapeutics―Targeting Nitazoxanide as Bactericidal and Host-Directed Agent to Macrophages in a Mouse Model of Tuberculosis. Molecular Pharmaceutics, 2016, 13, 3247-3255.	2.3	12
15	Targeted pulmonary delivery of inducers of host macrophage autophagy as a potential host-directed chemotherapy of tuberculosis. Advanced Drug Delivery Reviews, 2016, 102, 10-20.	6.6	29
16	Opportunities and Challenges for Host-Directed Therapies in Tuberculosis. Current Pharmaceutical Design, 2016, 22, 2599-2604.	0.9	26
17	Inhalable Particles Containing Rapamycin for Induction of Autophagy in Macrophages Infected with <i>Mycobacterium tuberculosis</i> . Molecular Pharmaceutics, 2014, 11, 1201-1207.	2.3	55
18	Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill Mycobacterium tuberculosis. Tuberculosis, 2013, 93, 412-417.	0.8	28

#	Article	IF	CITATIONS
19	Particulate Pulmonary Delivery Systems Containing Anti-Tuberculosis Agents. Critical Reviews in Therapeutic Drug Carrier Systems, 2013, 30, 277-291.	1.2	12
20	Inhalable Microparticles Containing Nitric Oxide Donors: Saying NO to Intracellular <i>Mycobacterium tuberculosis</i> . Molecular Pharmaceutics, 2012, 9, 3183-3189.	2.3	32